Savara Inc (SVRA) stock
SVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.48+0.02 (+0.34%)
Close on Nov 17, 2026Market cap $920.46MP/E –Yield –
Savara ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Savara's ebitda for the twelve months ending Jun 30, 2026 was -$143.55M. For fiscal 2025 it was -$123.46M. The highest annual figure on record is -$5.78M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.46M | – |
| FY2024 | Dec 31, 2024 | -$103.07M | – |
| FY2023 | Dec 31, 2023 | -$59.93M | – |
| FY2022 | Dec 31, 2022 | -$38.81M | – |
| FY2021 | Dec 31, 2021 | -$41.34M | – |
| FY2020 | Dec 31, 2020 | -$49.05M | – |
| FY2019 | Dec 31, 2019 | -$78.71M | – |
| FY2018 | Dec 31, 2018 | -$69.52M | – |
| FY2016 | Dec 31, 2016 | -$10.85M | – |
| FY2015 | Dec 31, 2015 | -$5.78M | – |
| FY2014 | Dec 31, 2014 | -$29.19M | – |
| FY2013 | Dec 31, 2013 | -$21.50M | – |
| FY2012 | Dec 31, 2012 | -$15.54M | – |
| FY2011 | Dec 31, 2011 | -$13.36M | – |
| FY2010 | Dec 31, 2010 | -$8.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$40.94M | – |
| Q1 FY2026 | Mar 31, 2026 | -$38.97M | – |
| Q4 FY2025 | Dec 31, 2025 | -$33.43M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.22M | – |
| Q2 FY2025 | Jun 30, 2025 | -$31.41M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.14M | – |
| Q3 FY2024 | Sep 30, 2024 | -$26.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$23.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.44M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.21M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$10.53M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.38M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.64M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.41M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.72M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.20M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$31.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$12.39M | – |
| Q2 FY2019 | Jun 30, 2019 | -$22.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.61M | – |
| Q4 FY2018 | Dec 31, 2018 | -$13.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$11.75M | – |
| Q1 FY2018 | Mar 31, 2018 | -$32.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.76M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.03M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.21M | – |
See a number that looks wrong?